Preclinical Pharmacokinetics, Toxicity and Therapeutic Evaluation of QD502

Preclinical Pharmacokinetics, Toxicity and Therapeutic Evaluation of QD502 | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Preclinical Pharmacokinetics, Toxicity and Therapeutic Evaluation of QD502 Lillianne H. Wright, Ying Meng, Shuai Mao, Joyeeta Roy, Armita Kyani, and 5 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-6050704/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract This preclinical study evaluates the pharmacokinetics, tolerability, and anticancer efficacy of QD502, a novel quinazolinone-based compound, in rodent models. Pharmacokinetic assessments were performed in male BALB/c mice and Sprague-Dawley rats after oral and intravenous administration. QD502's stability in plasma and simulated gastrointestinal fluids, as well as its potential to inhibit human cytochrome P450 (CYP450) enzymes, was also assessed. Acute (14-day) and chronic (28-day) toxicity studies determined the maximum tolerated dose (MTD) and safety profile. In vitro, QD502 showed potent cytotoxicity across various cancer cell lines with sub-micromolar IC50 values. Pharmacokinetic analysis revealed favorable characteristics, including stability in biological matrices and minimal interaction with major CYP450 isoforms. QD502 was well-tolerated at the tested doses, with no significant adverse effects observed. In a colorectal xenograft model, QD502 delayed tumor growth via both oral and intravenous administration without notable toxicity. These results suggest that QD502 possesses promising pharmacokinetic properties, strong anticancer activity, and limited toxicity, highlighting its potential for future cancer treatments. Biological sciences/Cancer Biological sciences/Drug discovery Quinazolinidiones oncology solid tumors pharmacokinetics drug discovery Full Text Additional Declarations No competing interests reported. Supplementary Files ScientificRep.SupplementalTablesandFigures22325.docx Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-6050704","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":422940417,"identity":"d685f3f9-1840-47dd-99a1-d26f1c770592","order_by":0,"name":"Lillianne H. Wright","email":"","orcid":"","institution":"KOR Life Sciences, LLC","correspondingAuthor":false,"prefix":"","firstName":"Lillianne","middleName":"H.","lastName":"Wright","suffix":""},{"id":422940418,"identity":"e4e3c91c-3fbd-4570-a1fc-5da68788497b","order_by":1,"name":"Ying Meng","email":"","orcid":"","institution":"University of Michigan–Ann Arbor","correspondingAuthor":false,"prefix":"","firstName":"Ying","middleName":"","lastName":"Meng","suffix":""},{"id":422940419,"identity":"2826a9d1-5488-4fac-b751-cc3dd6cec2e2","order_by":2,"name":"Shuai Mao","email":"","orcid":"","institution":"University of Michigan–Ann Arbor","correspondingAuthor":false,"prefix":"","firstName":"Shuai","middleName":"","lastName":"Mao","suffix":""},{"id":422940420,"identity":"009a15b5-81be-495f-ad8e-33379de17443","order_by":3,"name":"Joyeeta Roy","email":"","orcid":"","institution":"University of Michigan–Ann Arbor","correspondingAuthor":false,"prefix":"","firstName":"Joyeeta","middleName":"","lastName":"Roy","suffix":""},{"id":422940421,"identity":"19a02b7a-f5e4-4700-8a5b-bb1d00308995","order_by":4,"name":"Armita Kyani","email":"","orcid":"","institution":"University of Michigan–Ann Arbor","correspondingAuthor":false,"prefix":"","firstName":"Armita","middleName":"","lastName":"Kyani","suffix":""},{"id":422940422,"identity":"fd0bcf75-5576-4a7c-b14d-ea22f731655c","order_by":5,"name":"Imran Ansari","email":"","orcid":"","institution":"KOR Life Sciences, LLC","correspondingAuthor":false,"prefix":"","firstName":"Imran","middleName":"","lastName":"Ansari","suffix":""},{"id":422940423,"identity":"66660a5c-1be6-4266-9da9-bf779ce37163","order_by":6,"name":"Shea Harrelson","email":"","orcid":"","institution":"KOR Life Sciences, LLC","correspondingAuthor":false,"prefix":"","firstName":"Shea","middleName":"","lastName":"Harrelson","suffix":""},{"id":422940424,"identity":"e28cf2a5-881b-4895-bdae-c27f1c4ae8ab","order_by":7,"name":"Scotty Branch","email":"","orcid":"","institution":"KOR Life Sciences, LLC","correspondingAuthor":false,"prefix":"","firstName":"Scotty","middleName":"","lastName":"Branch","suffix":""},{"id":422940425,"identity":"d6249e79-8201-4070-84d3-bac43e4f71c1","order_by":8,"name":"Nouri Neamati","email":"","orcid":"","institution":"University of Michigan–Ann Arbor","correspondingAuthor":false,"prefix":"","firstName":"Nouri","middleName":"","lastName":"Neamati","suffix":""},{"id":422940426,"identity":"55483f88-a205-4b0a-9f01-21e6016c1a72","order_by":9,"name":"Saeed Khan","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABAElEQVRIie2RsWrDMBCGzxyky5msMir2ExQODF5qnGcxBk+ltHTJkCFTsqjNXCh9DM8KgmSxn6BLoS8QyGJooVUzlA6VvXbQBzokwQf/zwF4PP8RIjvmQOL0YnsweNXjSvtLIUQeV4IVgPj5AORBI1Hd9nj7bM6j9f3bob/Jr2dnGOgeivhi+bfC3UMlHxtDkvZZpLi+s8Fgq6BKM0c8nhLLsKkpFvUEgU2pcKoNgC4bh5JsKH0Pn04KHoE/rYIwqECnMhkuc5KiBgmsxxVu2+ySdjlFajexXapSme8u7O6SqKv0hRZiJvYrPPQfRbneGHuZF7FLcTG8Go/H4/GM8AW3hVA2Aqt10QAAAABJRU5ErkJggg==","orcid":"","institution":"KOR Life Sciences, LLC","correspondingAuthor":true,"prefix":"","firstName":"Saeed","middleName":"","lastName":"Khan","suffix":""}],"badges":[],"createdAt":"2025-02-17 20:08:16","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-6050704/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-6050704/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":83643917,"identity":"2e0b2f90-56fe-4265-9436-4b4db651a932","added_by":"auto","created_at":"2025-05-30 04:39:21","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1422292,"visible":true,"origin":"","legend":"","description":"","filename":"ScientificReportsLW22625.pdf","url":"https://assets-eu.researchsquare.com/files/rs-6050704/v1_covered_54bc41d8-08d6-4ead-8ca0-fb53d5052265.pdf"},{"id":77600125,"identity":"4059dbb7-d1c1-4770-bec5-1b3e3093815b","added_by":"auto","created_at":"2025-03-03 12:47:03","extension":"docx","order_by":0,"title":"","display":"","copyAsset":false,"role":"supplement","size":2812619,"visible":true,"origin":"","legend":"","description":"","filename":"ScientificRep.SupplementalTablesandFigures22325.docx","url":"https://assets-eu.researchsquare.com/files/rs-6050704/v1/dcb4fd61ba39ad3c77fc4f45.docx"}],"financialInterests":"No competing interests reported.","formattedTitle":"Preclinical Pharmacokinetics, Toxicity and Therapeutic Evaluation of QD502","fulltext":[],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":false,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":true,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":true,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Quinazolinidiones, oncology, solid tumors, pharmacokinetics, drug discovery","lastPublishedDoi":"10.21203/rs.3.rs-6050704/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-6050704/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eThis preclinical study evaluates the pharmacokinetics, tolerability, and anticancer efficacy of QD502, a novel quinazolinone-based compound, in rodent models. Pharmacokinetic assessments were performed in male BALB/c mice and Sprague-Dawley rats after oral and intravenous administration. QD502's stability in plasma and simulated gastrointestinal fluids, as well as its potential to inhibit human cytochrome P450 (CYP450) enzymes, was also assessed. Acute (14-day) and chronic (28-day) toxicity studies determined the maximum tolerated dose (MTD) and safety profile. In vitro, QD502 showed potent cytotoxicity across various cancer cell lines with sub-micromolar IC50 values. Pharmacokinetic analysis revealed favorable characteristics, including stability in biological matrices and minimal interaction with major CYP450 isoforms. QD502 was well-tolerated at the tested doses, with no significant adverse effects observed. In a colorectal xenograft model, QD502 delayed tumor growth via both oral and intravenous administration without notable toxicity. These results suggest that QD502 possesses promising pharmacokinetic properties, strong anticancer activity, and limited toxicity, highlighting its potential for future cancer treatments.\u003c/p\u003e","manuscriptTitle":"Preclinical Pharmacokinetics, Toxicity and Therapeutic Evaluation of QD502","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-03-03 12:30:57","doi":"10.21203/rs.3.rs-6050704/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"7eaf436b-af40-46ee-9356-1f1212b98e79","owner":[],"postedDate":"March 3rd, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":45076649,"name":"Biological sciences/Cancer"},{"id":45076650,"name":"Biological sciences/Drug discovery"}],"tags":[],"updatedAt":"2025-05-30T04:38:08+00:00","versionOfRecord":[],"versionCreatedAt":"2025-03-03 12:30:57","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-6050704","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-6050704","identity":"rs-6050704","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}